Cardiovascular diseases (CVDs) are one of the most common complications during long-term cancer treatment, yet how the genetic factors associated with the cardiovascular risk of antineoplastic drugs had not been investigating systematically. By integrating results of large-scale CVD genome-wide association studies and biological network information, we established a compendium of genetic evidence that support antineoplastic-induced cardiovascular risk at different levels. In this web site, users can obtain the detail of the result from the Cui et al through searching the key like, rsID, gene name and drug name.